Affronti ML, et al. - Given bevacizumab (BEV) combination therapies may be superior to single agent, researchers investigated if blocking vascular invasion and tumor proliferation may synergistically inhibit tumor growth in recurrent malignant glioma (rMG) treated by BEV combined with rilotumumab, a hepatocyte growth factor (HGF) antibody, that inhibits angiogenesis and expression of angiogenic autocrine factors (e.g., vascular endothelial growth factor [VEGF]) by c-Met inhibition. Relative to BEV alone, rilotumumab with BEV did not significantly improve objective response in BEV-naïve rMG subjects. Most frequent treatment-related grade ≤2 events (weight gain, fatigue, allergic rhinitis, and voice alteration) and grade ≥3 events (venous thromboembolism (four patients), including one death from pulmonary embolism) were reported. Overall, the effects, as well as toxicity, may preclude the use of rilotumumab in combination BEV regimens.